血管内皮生长因子165基因对人胃癌细胞凋亡的影响及机制  

Effect of vascular endothelial growth factor 165 on apoptosis of human gastric carcinoma cells in vitro and its mechanism

作　　者：欧希龙[1] 关云艳[1] 颜芳[1] 孙为豪[2] 杨柳[1] 陈国胜[2] 

机构地区：[1]东南大学附属中大医院消化内科,江苏省南京市210009 [2]南京医科大学第一附属医院老年消化科,江苏省南京市210029

出　　处：《世界华人消化杂志》2008年第3期307-310,共4页World Chinese Journal of Digestology

摘　　要：目的:本实验探讨血管内皮生长因子165(VEGF165)对体外培养的胃癌细胞株BGC-823凋亡的影响和机制.方法:将BGC-823细胞分为对照组、感染复数(MOI=20)病毒Ad-GFP的Ad-GFP组,重组腺病毒Ad-VEGF165转染的Ad-VEGF165组.应用流式细胞仪检测细胞凋亡的百分率,RT-PCR方法检测凋亡抑制基因Bcl-2mRNA的表达,免疫细胞化学方法检测Bcl-2蛋白的表达情况.结果:流式细胞仪测定显示Ad-VEGF165组的细胞凋亡率明显低于Ad-GFP组和对照组(4.6%±0.31% vs 8.37%±1.06%.7.73%±0.86%,P<0.01);RT-PCR和细胞免疫化学结果显示VEGF165转染BGC-823细胞后促进了细胞Bcl-2mRNA和蛋白的表达.Ad-VEGF165组Bcl-2mRNA和蛋白均高于对照组和Ad-GFP组(Bcl-2mRNA:0.761±0.05 vs 0.363±0.12.0.356±0.08;Bcl-2蛋白:1.010±0.08 vs 0.865±0.07,0.901±0.05;P<0.01).结论:VEGF165通过上调凋亡抑制基因Bcl-2及其蛋白的表达,来抑制血浆饥饿诱导的胃癌细胞的凋亡.AIM： To investigate the effect of vascular endothelial growth factor 165 （VEGF165） on apoptosis of human cell line （BGC-823） in mechanism gastic adenocarcinoma vitro and its underlying. METHODS： BGC-823 cells were divided into control group, Ad-GFP group and Ad-VEGF165 group and cultured with GFP （MOI = 20） and Ad-VEGF165. Apoptotic cells were detected by FCM assay. Expression of Bcl-2 mRNA and Bcl-2 protein was determined by RT-PCR and immunocytochemistry, respectively. RESULTS： FCM showed that the apoptosis rate of BGC-823 cells was significantly lower in the Ad-VEGF165 group than in the Ad-GFP and control groups（4.6% ± 0.31% vs 8.37% ± 1.06%, 7.73% ± 0.86%, P 〈 0.01）. PCR and immunocytochemistry displayed that VEGF165-transfected BGC-823 increased the expression of Bcl-2 mRNA and Bcl-2 protein, which was higher in the Ad-VEGF165 group than in the control and Ad-GFP groups （Bcl-2 mRNA： 0.761 ± 0.05 vs 0.363 ± 0.12, 0.356 ± 0.08; Bcl-2 protein： 1.010 ± 0.08 vs 0.865 ± 0.07, 0.901 ± 0.05; P 〈 0.01）. CONCLUSION： VEGF165 can inhibit cell apoptosis induced by serum starvation by up-regulating the expression of Bcl-2.

关 键 词：腺病毒 血管内皮生长因子165 胃癌 凋亡 BCL-2 逆转录聚合酶链式反应 

分 类 号：R735.2[医药卫生—肿瘤] R73-36[医药卫生—临床医学]